{"organizations": [], "uuid": "7fd0809b64b9142042cda56e7e54f79d00238e92", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lynparza-tablets-receive-eu-approv/brief-lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer-idUSFWN1SF0KS", "country": "US", "domain_rank": 408, "title": "BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-08T18:55:00.000+03:00", "replies_count": 0, "uuid": "7fd0809b64b9142042cda56e7e54f79d00238e92"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lynparza-tablets-receive-eu-approv/brief-lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer-idUSFWN1SF0KS", "ord_in_thread": 0, "title": "BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "eu", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Merck & Co Inc:\n* LYNPARZAÂ® (OLAPARIB) TABLETS RECEIVE EU APPROVAL FOR THE TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER\n* MERCK & CO INC - NEW TABLET FORMULATION REDUCES DOSING TO TWO TABLETS TWICE DAILY\n* MERCK - EMA APPROVED LYNPARZA TABLETS (300 MG TWICE DAILY) FOR USE AS A MAINTENANCE THERAPY WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T18:55:00.000+03:00", "crawled": "2018-05-09T12:17:37.001+03:00", "highlightTitle": ""}